Sulfamethoxazole-Trimethoprim合剤に関する基礎的, 臨床的研究

抄録

1) The in vitro anti-bacterial activity of trimethoprim (TMP) against clinically isolated organisms (Staphylococcus aureus, Klebsiella, Proteus and Escherichia coli) was found to be markedly intensified by the coexistence of sulfamethoxazole (SMX).
2) Some studies were made on the biological assay of TMP using the “band culture method” (test organism : Bacillus pumilus). PABA added to the assay media in order to eliminate the activity of coexistent SMX was found to affect the length of the inhibition zones produced by TMP.
3) Clinical trials : Thirty-five cases, including 16 of respiratory tract infections, 9 of urinary tract infections, two each of toxoplasmosis, colitis and lymphadenitis, one each of phlebitis, oto-furuncle, gingivitis and common cold, were treated with SMX-TMP combination product (2 tab.×2 daily, each tablet containing 400 mg SMX and 80 mg TMP). The treatment yielded satisfactory results in 9 cases of respiratory tract infections, 9 of urinary tract infections as well as in 4 of the remainder; while it failed in 6 cases. The clinical results were undeterminable in 7 cases, although, in two toxoplasmosis cases among them, antibody titer of their sera lowered after the treatment.
As for the side effects of the drug, glossitis and perleche were found in two patients who received the treatment more than 20 days. Three complained of anorexia. Although two patients showed anemia after the treatment, it was explainable as due to the infection.